Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)

被引：1
|
作者：
Moehler, M. [1 ]
Wyrwicz, L. [2 ]
Chen, C. [3 ]
Davenport, E. [4 ]
Wang, J. [4 ]
Nathani, R. [3 ]
Kondo, K. [3 ]
Elimova, E. [5 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Mainz, Germany
[2] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] RTI Int, Res Triangle Pk, NC USA
[5] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-10
引用
收藏
页码：S185 / S185
页数：1
相关论文
共 50 条
  • [41] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
  • [42] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, H-T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A. V.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Pazo Cid, R. A.
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1527
  • [43] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Cid, R. A. Pazo
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1320 - S1321
  • [44] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
    Jiang, Yuan
    Li, Yue
    Wang, Larry X. W.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (02) : 499 - 506
  • [45] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
    Yuan Jiang
    Yue Li
    Larry X. W. Wang
    International Journal of Clinical Pharmacy, 2022, 44 : 499 - 506
  • [46] Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
    Mansoor, Wasat
    Joo, Seongjung
    Norquist, Josephine M.
    Kato, Ken
    Sun, Jong-Mu
    Shah, Manish A.
    Enzinger, Peter
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li, Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chol
    Sunpaweravong, Patrapim
    Maqueda, Maria Alsina
    Goekkurt, Eray
    Suryawanshi, Shailaja
    Shah, Sukrut
    Shen, Lin
    ONCOLOGIST, 2024, 29 (10): : e1324 - e1335
  • [47] Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.
    Mansoor, Wasat
    Kulkarni, Amit S.
    Kato, Ken
    Sun, Jong-Mu
    Shah, Manish A.
    Enzinger, Peter C.
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chul
    Sunpaweravong, Patrapim
    Alsina, Maria
    Goekkurt, Eray
    Suryawanshi, Shailaja
    Norquist, Josephine
    Shah, Sukrut
    Shen Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [48] Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Lowery, M.
    Wyrwicz, L.
    Oh, D-Y.
    Shiu, K. K.
    Weber, P. Yanez
    Bai, Y.
    Lee, J.
    Rivera, F.
    Alves, G.
    Garrido, M.
    Fernandez, M. Gonzalez
    Li, J.
    Cil, T.
    Cruz, F.
    Qin, S.
    Yin, L.
    Valderrama, A.
    Bordia, S.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S854 - S855
  • [49] Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N plus C) vs pembrolizumab plus axitinib (P plus A) in previously untreated advanced renal cell carcinoma (aRCC)
    Porta, C. G.
    Motzer, R.
    Ejzykowicz, F.
    Blum, S. I.
    Hamilton, M.
    May, J. R.
    Huo, S.
    Kral, P.
    Ivanescu, C.
    Choueiri, T. K.
    Cella, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S692 - S693
  • [50] CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) plus ipilimumab (IPI) or nivo plus chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.
    Moehler, Markus H.
    Janjigian, Yelena Yuriy
    Adenis, Antoine
    Aucoin, Jean-Sebastien
    Boku, Narikazu
    Chau, Ian
    Cleary, James M.
    Feeney, Kynan
    Franke, Fabio A.
    Mendez, Guillermo Ariel
    Schenker, Michael
    Li, Mingshun
    Hitre, Erika
    Couture, Felix
    Karamouzis, Michalis
    Etienne, Pierre-Luc
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345